Esperite NV, of Amsterdam, said its biotechnology company, The Cell Factory, in collaboration with Women's and Children's Health Department of the University of Padua have developed the second generation of clinical-grade extracellular vesicles (EVs) enhanced with the protein annexin V (EV-AnV).